방법 비교

	아테네 불면증 척도(Athens Insomnia Scale, AIS)	불면증 심각도 지수 (ISI)	양성 및 음성 증후군 척도 (PANSS)
분야	정신의학	정신의학	정신의학
계열	Process / pipeline	Process / pipeline	Process / pipeline
기원 연도	2000	2001	1987
창시자	Christos R. Soldatos	Charles M. Morin	Stanley R. Kay
유형	Self-report questionnaire	Self-report questionnaire	Clinician-administered rating scale
원전	Soldatos, C. R., Dikeos, D. G., & Paparrigopoulos, T. J. (2000). Athens Insomnia Scale: Validation of an instrument based on ICD-10 criteria. Journal of Psychosomatic Research, 48(6), 555–560.	Morin, C. M., Belleville, G., Bélanger, L., & Ivers, H. (2011). The Insomnia Severity Index: Psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep, 34(5), 601–608.	Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2), 261–276.
별칭	AIS	ISI	PANSS
관련	3	3	3
요약	The AIS is an 8-item self-report scale designed to assess insomnia severity in adolescents and adults, based on ICD-10 diagnostic criteria for insomnia disorder. Developed by Soldatos and colleagues in 2000, it is widely used in European primary care, psychiatry, and sleep medicine for screening and severity assessment. The AIS is brief (3–5 minutes), applicable across ages and cultures, and sensitive to treatment-induced change in both pharmacological and behavioral interventions.	The ISI is a 7-item self-report questionnaire designed to assess the severity of insomnia in adolescents and adults. Developed by Morin and colleagues and validated in 2001, it measures difficulty falling asleep, difficulty staying asleep, early morning awakening, and daytime functional impairment due to sleep problems. The ISI is brief (2–3 minutes), psychometrically sound, and widely adopted in sleep research, primary care, and behavioral sleep medicine clinics for screening, baseline assessment, and treatment monitoring.	The PANSS is a 30-item clinician-administered scale designed to measure the presence and severity of positive symptoms (delusions, hallucinations, disorganization), negative symptoms (affective flattening, alogia, avolition), and general psychopathology in schizophrenia and related psychotic disorders. Developed by Kay, Fiszbein, and Opler in 1987, the PANSS has become the standard rating scale in schizophrenia research, antipsychotic medication trials, and clinical monitoring. It provides comprehensive assessment across three symptom domains and yields a total score reflecting overall disease severity.